Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes

Journal of Bone and Joint Surgery

Volumn 86, Issue 11, 2004, Pages 2412-2418

  Dickey, Ian D ^a   Rose, Peter S ^a   Fuchs, Bruno ^a   Wold, Lester E ^a   Okuno, Scott H ^a   Sim, Franklin H ^a   Scully, Sean P ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADJUVANT THERAPY; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHONDROSARCOMA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LUNG RESECTION; MALE; MEDICAL RECORD; MEDICAL SOCIETY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 8144226832     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-200411000-00008     Document Type: Review

References (19)

1. Dahiin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas. Cancer. 1971;28:461-6.
2. Capanna R, Bertoni F, Bettelli G, Picci P, Bacchini P, Present D, Giunti A, Campanacci M. Dedifferentiated chondrosarcoma. J Bone Joint Surg Am. 1988;70:60-9.
3. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000;82:55-61.
4. Mirra JM, Marcove RC. Fibrosarcomatous dedifferentiation of primary and secondary chondrosarcoma. Review of five cases. J Bone Joint Surg Am. 1974;56:285-96.
5. McFarland GB Jr, McKiniey LM, Reed RJ. Dedifferentiation of low grade chondrosarcomas. Clin Orthop. 1977;122:157-64.
6. Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am. 1986;68:1197-205.
7. Campanacci M, Bertoni F, Capanna R. Dedifferentiated chondrosarcomas. Ital J Orthop Traumatol. 1979;5:331-41.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
9. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [Ser A]. 1972;135:185-207.
10. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, IA: Iowa State University Press; 1980. p 75-8.
11. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames, IA: Iowa State University Press; 1967. p 100-6.
12. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: Wiley; 1973. p 68-75.
13. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop. 1986;204:9-24.
14. Frassica FJ, Unni KK, Sim FH. Case report 347. Dedifferentiated chondrosarcoma: grade 4 fibrosarcoma arising in grade 1 chondrosarcoms (femur). Skeletal Radiol. 1986;15:77-81.
15. O'Malley DP, Opheim KE, Barry TS, Chapman DB, Emond MJ, Conrad EU, Norwood TH. Chromosomal changes in a dedifferentiated chondrosarcoma: a case report and review of the literature. Cancer Genet Cytogenet. 2001;124:105-11.
16. Sakamoto A, Oda Y, Adachi T, Oshiro Y, Tamiya S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M. H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis. Mod Pathol. 2001;14:343-9.
17. Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol. 1999;125:541-8.
18. Johnson S, Tetu B, Ayala AG, Chawia SP. Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases. Cancer. 1986;58:278-86.
19. Terek RM, Schwartz GK, Devaney K, Giantz L, Mak S, Healey JH, Albino AP. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res. 1998;16:585-90.